Style | Citing Format |
---|---|
MLA | Khodabakhsh P, et al.. "Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype." Stem Cell Reviews and Reports, vol. 20, no. 1, 2024, pp. 394-412. |
APA | Khodabakhsh P, Asgari Taei A, Shafaroodi H, Pournajaf S, Dargahi L (2024). Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype. Stem Cell Reviews and Reports, 20(1), 394-412. |
Chicago | Khodabakhsh P, Asgari Taei A, Shafaroodi H, Pournajaf S, Dargahi L. "Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype." Stem Cell Reviews and Reports 20, no. 1 (2024): 394-412. |
Harvard | Khodabakhsh P et al. (2024) 'Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype', Stem Cell Reviews and Reports, 20(1), pp. 394-412. |
Vancouver | Khodabakhsh P, Asgari Taei A, Shafaroodi H, Pournajaf S, Dargahi L. Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype. Stem Cell Reviews and Reports. 2024;20(1):394-412. |
BibTex | @article{ author = {Khodabakhsh P and Asgari Taei A and Shafaroodi H and Pournajaf S and Dargahi L}, title = {Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype}, journal = {Stem Cell Reviews and Reports}, volume = {20}, number = {1}, pages = {394-412}, year = {2024} } |
RIS | TY - JOUR AU - Khodabakhsh P AU - Asgari Taei A AU - Shafaroodi H AU - Pournajaf S AU - Dargahi L TI - Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype JO - Stem Cell Reviews and Reports VL - 20 IS - 1 SP - 394 EP - 412 PY - 2024 ER - |